C12N 2501/2327
Interleukin-27
Official title: Interleukin-27 (IL-27)
C12N2501/2327 (Interleukin-27) appears on 7 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 18
- Assignees
- 19
- Inventors
- 51
- Latest grant
- 4 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 2 |
| 2023 | 2 | 3 |
| 2024 | 2 | 2 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Modulation of novel immune checkpoint targets4 Mar 2025US 12,241,053 B2Massachusetts Institute of Technology
- Composition for culturing NK cells and method for culturing NK cells using same14 May 2024US 11,981,924 B2Sungkwang Medical Foundation
- Compositions and methods for the isolation and/or generation of specific CD4+ and CD8+ T-cell subsets9 Apr 2024US 11,951,128 B2La Jolla Institute for Allergy and Immunology
- Composition for culturing NK cells and method for culturing NK cells using same5 Sep 2023US 11,746,327 B2Sungkwang Medical Foundation
- Method for producing B cell population and method for producing monoclonal antibody using same14 Feb 2023US 11,578,132 B2Kaneka Corporation
- Combination of engineered natural killer (nk) cells and antibody therapy and related methods11 Dec 2025US 2025/0375524 A1Indapta Therapeutics, Inc.
- Mesenchymal stem cells treated by at least two of cytokines il4, il21, and il27, exosomes and uses thereof28 Nov 2024US 2024/0390426 A1Shenzhen Beike Biotechnololgy Co., Ltd
- Engineered natural killer (nk) cells and related methods26 Sep 2024US 2024/0316102 A1Indapta Therapeutics, Inc.
- Composition for culturing nk cells and method for culturing nk cells using same16 Nov 2023US 2023/0365932 A1Sungkwang Medical Foundation
- Method of producing tumor-reactive t cell composition using modulatory agents2 Feb 2023US 2023/0032934 A1Myst Therapeutics, LLC
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.